Skip to main content

Table 2 Trends of Changes in Clinical Presentation in Aloe vera and Placebo During a Six-Week Follow-up

From: Prevention of acute radiation-induced Proctitis by Aloe vera: a prospective randomized, double-blind, placebo controlled clinical trial in Pelvic Cancer patients

 

Week

Effect

1

Median (Q1,Q3)a

6

Median (Q1,Q3)a

Within group

Between group

Rectal Bleeding

Aloe vera

< 0.001 (< 0.001- < 0.001)

< 0.001 (< 0.001- < 0.001)

0.55

< 0.001

Placebo

< 0.001 (< 0.001- < 0.001)

< 0.001 (< 0.001–1)

0.04

Rectal Pain

Aloe vera

< 0.001 (< 0.001–1)

< 0.001 (< 0.001- < 0.001)

0.15

0.14

Placebo

< 0.001 (< 0.001–1)

1 (< 0.001–2)

< 0.001

Diarrhea

Aloe vera

< 0.001 (< 0.001- < 0.001)

< 0.001 (< 0.001- < 0.001)

0.54

< 0.001

Placebo

< 0.001 (< 0.001- < 0.001)

1 (1–1.25)

< 0.001

Fecal urgency

Aloe vera

< 0.001 (< 0.001- < 0.001)

< 0.001 (< 0.001- < 0.001)

0.42

0.001

Placebo

< 0.001 (< 0.001- < 0.001)

1 (< 0.001–1)

< 0.001

Total Clinical Symptoms

Aloe vera

< 0.001 (< 0.001–1)

< 0.001 (< 0.001–0.75)

0.13

< 0.001

Placebo

< 0.001 (< 0.001–1)

2.5 (1.75–4.25)

< 0.001

Proctitis

Aloe vera

< 0.001 (< 0.001- < 0.001)

< 0.001 (< 0.001- < 0.001)

0.7

0.92

Placebo

< 0.001 (< 0.001- < 0.001)

< 0.001 (< 0.001- < 0.001)

0.65

Cystitis

Aloe vera

1 (< 0.001–1)

0.5 (< 0.001–1.75)

0.7

0.91

Placebo

< 0.001 (< 0.001–1)

1 (< 0.001–2)

0.06

RTOG Total

Aloe vera

1 (< 0.001–1)

0.5 (< 0.001–1.75)

0.8

0.03

Placebo

1 (< 0.001–2)

2 (1–3)

< 0.001

QOL

Aloe vera

< 0.001 (< 0.001- < 0.001)

< 0.001 (< 0.001- < 0.001)

0.74

< 0.001

Placebo

< 0.001 (< 0.001- < 0.001)

1 (< 0.001–1)

0.001

CRP

Aloe vera

5.1 (2.1–11)

2.5 (2.0–4.5)

0.02

0.009

Placebo

4.9 (2.0–6.3)

7.1 (4.27–17.2)

0.001

  1. RTOG radiation therapy oncology group, QOL Quality of life, CRP C-Reactive Protein
  2. a median [Percentile 25th - 75th]
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us